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In human cell-processed therapeutic products (hCTPs) for clinical application, tumorigenic cellular im-
purities in the manufacturing process are a major concern. Because cellular immortalization is one of the
prerequisite steps in tumorigenesis, we tested whether cell growth analysis can be employed to check for
immortalized (and potentially tumorigenic) cellular impurities in hCTPs. We monitored the growth of
human bone marrow-derived mesenchymal stem cells (BMSCs) mixed with HeLa cells at a ratio of 1/106
or more and compared their growth rates with that of BMSCs alone. The cell growth analysis detected a
signiﬁcant increase in the growth rate of the BMSCs spiked with 0.0001% HeLa within 30 days at a
probability of 47%. When human adipose-derived stem cells (ADSCs) were spiked with ASC52telo cells, a
human telomerase reverse transcriptase (hTERT)-immortalized adipose-derived mesenchymal stem cell
line, at a ratio of 0.001% or more, their growth rates were signiﬁcantly increased within 15 passages,
compared with that of ADSCs alone. These results indicate that cell growth analysis for the detection of
immortalized cellular impurities in human somatic stem cells is simple and can be useful for the quality
assessment of hCTPs in the manufacturing process.
© 2016, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
It is strongly expected that human cell-processed therapeutic
products (hCTPs) will be developed to treat diseases that are
currently life-threatening or incurable. The tumorigenic cellularpeutic product; BMSC, bone
se-derived stem cell; hTERT,
an mesenchymal stem cell;
Eagle's medium; PBS, phos-
titative reverse transcription
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se Society for Regenerative
ative Medicine. Production and hoimpurities of hCTPs are a major concern for the clinical application
of hCTPs. Unlike human pluripotent stem cells (i.e., embryonic stem
cells and induced pluripotent stem cells [1,2]), human somatic cells
are thought to have little tumorigenicity, regardless of the in vitro
cell processing [3,4]. To the best of our knowledge, only three
studies (therapies of ataxia telangiectasia with human fetal neural
stem cells, spinal cord injury with olfactory mucosal cells, and full-
thickness burn with cultured epidermal autograft) have reported
tumor formation following the transplantation of human somatic
cells into patients [5e7]. Four individual groups have reported the
spontaneous transformation of human mesenchymal stem cells
(hMSCs) after long-term in vitro culture [8e11]. However, two of
these research papers were later retracted due to the cross-
contamination of hMSCs with tumorigenic cells [12,13]. In the
other two papers, the immortalization of hMSCs was initially found
in the in vitro culture, which is closely associated with tumorige-
nicity [10,11]. These observations suggest that avoidingsting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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growth of immortalized cells without senescence is critical for the
quality control of hCTPs derived from human somatic stem cells. In
fact, the European Medicines Agency has stated that the evaluation
of in vitro cell senescence after serial passaging is sufﬁcient to prove
the absence of immortalized/tumorigenic cells in human somatic
cell-based products [14].
In a previous study, we examined the growth rates of human
bone marrow-derived mesenchymal stem cells (BMSCs) spiked
with various doses of HeLa cells to determine the sensitivity of cell
growth analysis for the detection of immortalized (and potentially
tumorigenic) cells contained in somatic stem cells as impurities.
The results indicated that as little as 0.001% of HeLa cells as im-
purities were detectable by cell growth analysis [15]. Here we
attempted to detect 0.0001% of HeLa cells spiked into BMSCs to
further conﬁrm the sensitivity of cell growth analysis. We also
characterized the performance of the cell growth analysis as a
testing method for immortalized cellular impurities that show
more modest growth, compared with HeLa cells, using human
adipose-derived mesenchymal stem cells (ADSCs) and immortal-
ized human telomerase reverse transcriptase (hTERT)-transduced
ADSCs. Our data suggest the usefulness of cell growth analysis for
the quality assessment for hCTPs.
2. Materials and methods
2.1. Cells
All of the cell cultures were maintained in a humidiﬁed atmo-
sphere of 5% CO2 and 95% air at 37 C. BMSCs at passage 2 (P ¼ 2)
and ADSCs at P ¼ 1 were purchased from Lonza. ASC52telo cells,
hTERT-immortalized adipose-derived mesenchymal stem cells,
were obtained from ATCC. HeLa cells were obtained from the
Health Science Research Resources Bank (Osaka, Japan). BMSCs
were cultured in an MSCGM BulletKit™, a mesenchymal stem cell
basal medium supplemented with mesenchymal cell growth sup-
plement, L-glutamine, and gentamycin/amphotericin-B (Lonza).
ADSCs and ASC52telo cells were cultured in an ADSC-BulletKit™,
an ADSC basal medium supplemented with the necessary supple-
ments (Lonza). HeLa cells were cultured in Eagle's minimum
essential medium supplemented with 10% fetal bovine serum (FBS;
Sigma), 0.1 mM non-essential amino acids (Gibco), 50 U/ml peni-
cillin, and 50 mg/ml streptomycin (Gibco). Until they were used for
cell growth analysis, cells were maintained in the medium as
described above and passaged upon reaching 90% conﬂuence.
2.2. Cell growth analysis
At P ¼ 5 of BMSCs and ADSCs, 1  106 cells of BMSCs and ADSCs
were spiked with HeLa cells (10 or 1 cells) and ASC52telo cells
(1000, 100, or 10 cells), respectively. The spiked cells were prepared
by the serial dilution of counted cells. The cell suspensions were
seeded into T175 ﬂasks (Corning) and maintained in 40 ml of
Dulbecco's modiﬁed Eagle's medium (DMEM; Gibco) supple-
mented with 10% FBS (Sigma), 50 U/ml penicillin, and 50 mg/ml
streptomycin (Gibco). Upon reaching approximately 90% conﬂu-
ence, the cells were rinsed with phosphate buffered saline (PBS;
Nacalai Tesque, Kyoto, Japan) and treated with 0.05% trypsin-EDTA
solution (Gibco) for detachment from the ﬂasks. The cells were
centrifuged at 450  g for 5 min and suspended with the fresh
culture medium. Aliquots of the suspended cells were stained with
0.4% trypan blue solution and counted using a Countess automated
cell counter (Invitrogen) according to the manufacturer's protocol.
One million cells in the suspension were re-seeded into T175 ﬂasks
and cultured until the next passage. These procedures wererepeated by P ¼ 11 and P ¼ 20 in the experiments using the BMSCs
spiked with HeLa cells and ADSCs spiked with ASC52telo cells,
respectively. The growth rate (Rn) at P ¼ n was calculated by the
following equation:
Rn ¼ ½log2ðNnþ1=NnÞ=ðDnþ1  DnÞ;
where Nk and Dk are the number of accumulated cells and the date
at P ¼ k, respectively.
2.3. Quantitative reverse transcription polymerase chain reaction
(qRT-PCR)
Total RNA was isolated from ASC52telo cells spiked into ADSCs
using an RNeasy Mini Kit with DNase I treatment (QIAGEN) ac-
cording to the manufacturer's instructions. RNA concentration was
measured using the NanoDrop ND-1000 (Thermo Fisher Scienti-
ﬁc). qRT-PCR was performed with a QuantiTect Probe RT-PCR Kit
(QIAGEN) on a 7300 Real-Time PCR System (Applied Biosystems).
The PCR condition was as follows. After initial incubations at 50 C
for 30 min and 95 C for 15 min, 40 cycles of ampliﬁcation were
carried out at 95 C for 15 s and 60 C for 1 min. Total RNA (5 ng
per sample) was used for analysis. The levels of hTERT expression
were normalized by those of GAPDH expression, which were
quantiﬁed using TaqMan human GAPDH control reagents (Applied
Biosystems). Primers and probes incorporating 50-FAM reporter
dye and 30-TAMRA quencher dye for qRT-PCR were obtained from
SigmaeAldrich. The primer and probe sequences targeting hTERT
gene were as follows: 50-CCTGTTTCTGGATTTGCAGGTG-30 (forward
primer), 50-GCACACATGCGTGAAACCTG-30 (reverse primer), and
50-CAGCCTCCAGACGGTGTGCACCAAC-30 (probe).
3. Results and discussion
In our previous cell growth analysis, 10 HeLa cells spiked into
1 106 BMSCs (0.001%) showed a signiﬁcant increase in the growth
rate within 30 days [15]. Here we added a single HeLa cell (HeLa 1)
or ten HeLa cells (HeLa 10) to 1  106 of BMSCs at P ¼ 5 and
monitored the number of cultured cells until P¼ 11. Although equal
proportion assay of spiking 10 cells into 1  107 cells (0.0001%)
appears to be more reproducible than that of spiking a single cell
into 1  106 cells, we had technical difﬁculties in handling 1  107
cells of BMSCswith one culture dish. Considering the varied growth
efﬁcacy of a single HeLa cell, we performed experiments with ten
samples of HeLa 1 for each lot of BMSCs. In contrast, we have
previously reported that the results of HeLa 10 and BMSCs alone
(HeLa 0) were convinced [15]. Here we determined to use BMSCs at
P ¼ 5 for the spike experiments because over 70% of clinical trials
have used hMSCs from 1 to 5 passages [16]. BMSCs alone (HeLa 0)
proliferated at almost constant rates during our observation (Fig. 1).
As expected, the cell growth of HeLa 10 was distinct from that of
HeLa 0within 30 days. Several samples of HeLa 1 also indicated that
their cell growth curves were rapidly accelerated within 30 days
compared with those of HeLa 0. In contrast, cell growth in some
samples of HeLa 1 did not differ from HeLa 0. The incidence rates of
accelerated cell growth were 47 ± 9% when one HeLa cell was
spiked into three lots of 1  106 BMSCs at the ratio of 0.0001%
(Table 1). Next, we calculated the growth rates (Rn) according to the
formula described in the Materials and methods section, and per-
formed a statistical analysis to determine the passage number that
showed a signiﬁcant difference in growth rates compared with
HeLa 0 at P ¼ 5. The growth rates in HeLa 1 with accelerated cell
growth gradually increased at P ¼ 8 and were signiﬁcantly higher
than that in HeLa 0 at P ¼ 5 (Fig. 2). These results indicated that cell
growth analysis detects HeLa cells as 0.0001% impurities of
Fig. 1. Time course of the cell growth of BMSCs spiked with HeLa cells. One million
BMSCs at passage 5 were mixed with none, 1, or 10 of HeLa cells (HeLa 0, HeLa 1, or
HeLa 10, respectively) and cultured by passage 11 as described in the Materials and
methods section. Ten samples spiked with one HeLa cell were used for each experi-
ment with one lot of BMSCs. The results of three lots of BMSCs are presented.
Fig. 2. Cell growth rate analysis of BMSCs spiked with HeLa cells. The growth rates of
BMSCs spiked with one HeLa cell are plotted along the passage numbers after mixing
with HeLa cells. HeLa 1 (þ) represents the group of BMSCs spiked with one HeLa cell
showing accelerated cell growth. HeLa 1 () represents the group of BMSCs spiked
with one HeLa cell showing no accelerated cell growth. Data are represented as the
mean ± standard error of the mean (SEM) of the three lots. Statistical signiﬁcance was
determined using two-way repeated measures analysis of variance (ANOVA) and the
Student-Newman-Keulis's post-hoc test (**P < 0.001 or *P < 0.05 compared with the
rate of HeLa 0 at P ¼ 5).
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with a 47% probability, which is the incidence rate of HeLa cells
showing accelerated cell growth. To assess hCTP quality associated
with safety, we need to avoid false negative results resulting from
the failure to detect immortalized/transformed cells [14,15]. The
false negative rate of one sample (x) was calculated as follows:Table 1
The incidence rates of accelerated cell growth when one HeLa cell was spiked into
BMSCs.
Lot. HeLa 1 Incidence rate (%)
þ 
A 6 4 60
B 5 5 50
C 3 7 30
Average 47 ± 9a
a Values are means ± SEM of three lots.x ¼ 1e0.47 ¼ 0.53. The false negative rate of n samples (y) can be
expressed as follows: y ¼ xn. Hence we obtain: n ¼ log y/log x.
When the tests permit a 1% false negative rate, the n of samples can
be calculated as follows: n ¼ log (0.01)/log (0.53) ¼ 7.25. Thus, 8
samples are necessary to prove the absence of 0.0001% immortal-
ized cells comparable to HeLa cells in hCTPs with a growth property
similar to BMSCs'.
HeLa cells are well-known immortalized/tumorigenic cells that
are used as the control in common tumorigenicity tests with cell
substrates for biological products [17]. We also attempted to detect
another immortalized cell line, ASC52telo cells, which are hTERT-
immortalized adipose-derived mesenchymal stem cells, contained
in ADSCs as impurities, by using cell growth analysis. We spiked
1  103 (ASC52telo 0.1%), 1  102 (ASC52telo 0.01%), and 1  10
(ASC52telo 0.001%) of ASC52telo cells into 1  106 three lots of
ADSCs at P ¼ 5 and cultured them until P ¼ 20 (Fig. 3). The
ASC52telo cells alone proliferated almost constantly during their
culture. On the other hand, all three lots of ADSCs containing
ASC52telo cells quickly increased their cell growth at some time
points, depending on the number of the spikedASC52telo cells. The
cell growth rates of ADSCs alone (ASC52telo 0%) gradually
decreased over the course of time and ﬁnally reached doubling
rates/day of less than 0.1, likely due to the process of normal cell
aging (Fig. 4). The cell growth rates in ASC52telo 0.1% were signif-
icantly higher than those in ADSCs alone after P ¼ 15. ASC52telo
0.01% and ASC52telo 0.001% began to show signiﬁcant difference in
the cell growth rates at P ¼ 16 and P ¼ 20, respectively. The cell
growth rate of ASC52telo cells slowly increased in the culture but
not quickly, suggesting that whole cell adaptation to their culture
condition occurred. As ASC52telo cells are similar to ADSCs in
respect to morphology, we had difﬁculty distinguishing between
ASC52telo cells and ADSCs under the microscope (Fig. S1). To
conﬁrm the impurities of ASC52telo cells in ADSCs, we consecu-
tively measured the levels of hTERT transcript, which were exclu-
sively expressed in ASC52telo cells, using qRT-PCR. hTERT mRNA
was not detected in ADSCs alone during 15 passages after the
spiking of ASC52telo cells under our experimental conditions. At
the beginning of cell growth analysis, the levels of hTERT mRNA
were dependent on the number of ASC52telo cells spiked in ADSCs.
The levels of hTERT mRNA in all of the groups of ADSCs mixed with
ASC52telo cells were gradually increased in successive passages
and reached to the level comparable to that in ASC52telo cells
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Fig. 3. Time course of the cell growth of ADSCs spiked with ASC52telo cells. One million ADSCs at passage 5 were mixed with 0, 10, 100, or 1000 of ASC52telo cells (ASC52telo 0%,
ASC52telo 0.001%, ASC52telo 0.01%, or ASC52telo 0.1%, respectively) and cultured as described in the Materials and Methods section. ASC52telo cells alone were cultured as the
control. The cells were passaged and counted at the indicated day from passage 5 until passage 20. The results of three lots of ADSCs are presented.
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(Fig. 5). These results indicated that most ADSCs were replaced
with ASC52telo cells within 15 passages after the spiking in the cell
growth analysis, even when as few as 0.001% ASC52telo cells were
contained in ADSCs.
Cell growth analysis has great potential to detect a small amount
of immortalized cellular impurities in hCTPs, even when the
growth of the immortalized cells is relatively slow compared with
HeLa cells. In the present study, the difference in the growth rate
between ADSCs and ASC52telo cells was not so obvious as between
BMSCs and HeLa cells, which makes difﬁcult the detection of the
immortalized cellular impurities by comparing the growth rate at
an early passage with that at a later passage. These results suggest
that negative time control data may be necessary to detectimmortalized cellular impurities, when their growth rate is
assumed to be modest.
We have recently reported several other methods for the
detection of immortalized or tumorigenic cellular impurities in
hCTPs besides cell growth analysis [15]. Digital analysis of soft agar
colony formation, using a high-content image analyzer, can detect
as little as 0.00001% HeLa cells in BMSCs [18]. In terms of sensitivity,
this method is far superior to cell growth analysis. However, in
principle, soft agar colony formation assay cannot be applied to
immortalized cells not growing in agar. In fact, induction for a
tumorigenic conversion upon hTERT transduction has not been
shown with soft agar assays [19,20]. In vivo tumorigenicity testing
using severely immunodeﬁcient NOG mice is available to detect
tumorigenic cells. They show tumor formation in one out of six
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were cultured, and their total RNAwas extracted. The mRNA levels of hTERT in the cells
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alone (ASC52telo 0%) during their culture period. ASC52telo 0.001% did not show any
expression of hTERT mRNA until 6 passages of ADSCs. Data are represented as the
mean ± SEM of the triplicate experiments.
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subcutaneously [21]. In vivo tumorigenicity testing has an advan-
tage of reﬂecting the in vivo microenvironment where hCTPs are
transplanted. However, in vivo tests are costly and laborious.
Appropriate methods should be chosen among the various
tumorigenicity and related testings to evaluate immortalized or
tumorigenic cellular impurities in hCTPs, taking the purpose and
performance of the testings into consideration for decision making
during the development of hCTPs [22]. We believe that the cell
growth analysis characterized herein can contribute to the quality
assessment of hCTPs and will suitably expedite cell therapy and
regenerative medicine.
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